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Insulin-reactive CD8 Tcells are amongst the earliest islet-infiltrating CD8 Tcells in NOD
mice. Cloned insulin B15–23-reactive cells (designated G9C8), restricted by H-2K
d, are
highly diabetogenic. We used altered peptide ligands (APL) substituted at TCR contact
sites, positions (p)6 and 8, to investigate G9C8 Tcell function and correlated this with
structure. Cytotoxicity and IFN-c production assays revealed that p6G and p8R could
not be replaced by any naturally occurring amino acid without abrogating recognition
and functional response by the G9C8 clone. When tested for antagonist activity with
APL differing from the native peptide at either of these positions, the peptide variants,
G6H and R8L showed the capacity to reduce the agonist response to the native peptide.
The antagonist activity in cytotoxicity and IFN-c production assays can be correlated
with conformational changes induced by different structures of the MHC-peptide
complexes, shown by molecular modeling. We conclude that p6 and p8 of the insulin
B15–23 peptide are very important for TCR stimulation of this clone and no
substitutions are tolerated at these positions in the peptide. This is important in
considering the therapeutic use of peptides as APL that encompass both CD4 and CD8
epitopes of insulin.
Supporting Information for this article is available at
http://www.wiley-vch.de/contents/jc-2040/2007/37762_s.html
Introduction
Altered peptide ligands (APL) are peptide variants of the
agonist peptide that are substituted at TCR contact sites
[1–3]. More rarely, peptides with substitutions at MHC
binding sites have also shown interesting properties as
APL [4, 5] such as stimulation of partial agonist
responses [5]. However, even though APL are very
close in amino acid sequence to the native peptide, they
induce a differential Tcell function profile [2, 6]. Some
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the agonist peptide, but not others, i.e. cytotoxicity or
production of cytokines without proliferation [1].
Others can induce a different cytokine profile [7],
induce anergy [1, 8], or inhibit the agonist response [9,
10]. Partial agonists can induce some but not all the
agonist T cell responses; antagonists inhibit the agonist
response in presence of the native peptide; and null
ligands are not recognized by the TCR [3].
Studies in both CD4 and CD8 T cell systems have
shown that APL can behave as antagonists and affect
several cell functions including cytotoxic responses,
cytokine production, serine esterase release, phospho-
inositol hydrolysis and calcium influx [10–12]. Investi-
gations using superantigen and peptide antigen that
bind to different sites of the MHC molecules, indicated
that in some instances, APL could antagonize a super-
antigen-mediated T cell response ruling out MHC
competition in those examples of APL antagonism [13].
We have previously isolated a highly pathogenic
CD8 T cell clone, G9C8, from the NOD mouse that
recognizes the insulin (Ins) B15–23 peptide [14, 15].
The peptide is within the B9–23 region that is
autoantigenic for CD4 T cells both in the NOD mouse
and in man [16, 17] and an APL has been used in an
immunotherapy trial [18]. The B15–23 peptide se-
quence, LYLVCGERG is unusual because peptides
presented by K
d often have a large hydrophobic residue
such as leucine or isoleucine at position 9 (p9) [19]
whereas this peptide has glycine, the smallest amino
acid.
The motif for H-2K
d predicts that there should be an
aromatic residue at p2, such as tyrosine or phenylala-
nine, and a large hydrophobic aliphatic residue at p9
[19, 20]. Structural homology modeling has shown that
the native Ins B15–23 peptide fits into the groove with
the p2Y providing the primary anchor, and the p9G the
secondary anchor, mainly through its free carboxylate
end [21]. Only afewpeptideresidues are responsible for
the specific recognition by the TCR [2]. Those amino
acids within the peptide sequencethat are recognized by
specific TCR and play a crucial role in the TCR/MHC-
peptide binding are known as primary contact sites [2].
Secondary contact sites are also involved in this
interaction but play a lesser role inTCR recognition [2].
In this study, we have identified Ins B15–23 APL that
antagonize the TCR of this highly pathogenic CD8 Tcell
clone, G9C8, focusing on APL for Ins B15–23 at p6 and
p8 of the nonamer peptide, since these are important
TCR contact sites [21]. None of the peptides altered at
these positions binds any better to the MHC, nor do they
stimulate any response from the cloned T cells.
Furthermore, many of them are able to antagonize
cytotoxic responses and IFN-c responses. We have
focused on the substitutions G6H and R8L and examine
structural reasons why this may be so and correlate the
structure with the functional response.
Results
Stimulation assays
Our previous studies had shown that conformation of
the region around residues p6 and p8 of the Ins B15–23
peptide is crucial, and not even conservative substitu-
tions were tolerated by the cognate TCR [21]. We
therefore tested for cytotoxic function, IFN-c production
and proliferation when replacing the native peptide Ins
B15–23 by every possible natural amino acid substitu-
tion at either p6 or p8.
The G9C8 cloned T cells were used as effectors in a
standard
51Cr-release assay against P815 target cells
after incubation with six different concentrations of the
peptides ranging from 0.0016–5 lg/mL (Fig. 1A). No
stimulation was seen above the background (no
peptide) for any of the substituted peptides or the
two control peptides for any of the six concentrations of
peptide tested (Fig. 1B and data not shown).
The G9C8 cells produce IFN-c with increasing
concentrations of peptide (Fig. 1A) and again, none of
the p6 and p8 substituted peptides induced anycytokine
production (Fig. 1C). Similarly, although G9C8 cells
clearly proliferate to Ins B15–23 peptide (Fig. 1A), no
proliferation was seen with any of the p6 or p8
substitutedpeptides(datanotshown).Thisisincontrast
to substitutions (even non-conservative ones) at p5, 7
and 9, where several substituted peptides were recog-
nized in complex with H2-K
d at lower concentrations
than the native peptide, by the G9C8 cells, resulting in
cellular proliferation, IFN-c secretion and cytotoxicity
[21].
Thus, the systematic replacement of p6 and p8 of the
native Ins B15–23 peptide by every other amino acid
revealed that the TCR contact residues p6G and p8R
could notbe replaced without abrogating recognition by
the G9C8 cells and loss of functional responses.
Antagonist cytotoxicity and IFN-c assays
Each of the substituted peptides was tested in antagonist
cytotoxic assays and IFN-c production assays. All the
peptide variants reduced lysis to a greater or lesser
extent. However, three peptides (G6H, G6I, G6L) induce
>50% antagonism at a peptide concentration of 0.1 lg/
mL, a concentration >50 times lower than the native
peptideconcentrationused intheassay.The antagonism
shown by G6H is illustrated in Fig. 2A. The substituted
p8 peptides were less effective, overall, although a
similar antagonism effect in the assays was seen with
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and R8L mutant peptides is shown in Fig. 3.
Binding assay results
To evaluate the binding of the APL to the MHC, binding
assays for each altered peptide at both p6 and p8 were
performed and results are shown in Fig. 4. The binding
of the APL at p6 and p8 of the Ins B15–23 peptide is
extremely weak in this binding assay and no substituted
peptide showed MHC-binding capacity greater than the
native peptide. Thus, the ability of the peptides to
antagonize the T cell functions is not related to
competition for MHC binding with the native peptide
as the altered peptides bound to the MHC more weakly
compared to the native peptide.
Molecular modeling
The results of molecular structural simulation, based on
the crystal structure of a H2-K
d nucleoprotein peptide
complex, show that the orientation of the Ins peptide in
the groove is mostly the same (with the exception of
residues p5C and p7E) as that obtained by modeling
based on the HLA-A2-Tax peptide complex [21]
(Fig. 5A). Remarkably, the crucial TCR contact residues
p6G/p8R remain in nearly identical orientations as in
the previous simulation (see below). There is a minor
shift in the anchoring of the peptide, as it is now shown
in this work, compared to previously [21], that the p5
residue in this peptide points into the groove (pocket C,
[22]). Furthermore, p7 is shown to be pointing towards
the a2 helix and away from the groove, hence just
outside the canonical “footprint” of the cognate T cell
receptor [23]. Assuming that the T cell receptor docks
onto this complex in a diagonal manner as suggested by
nearlyallstructuresofsuchcomplexes,weconcludethat
p5C and p7E participate only slightly inTCR recognition
[24–28]. The position of p8R is nearly on the same level
and in front of the a1 helix of H2-K
d. We find it
significant that in both molecular simulations, based on
HLA-A2 [21], and H2-K
d crystal structures (this work),
the relative orientations of p6G and p8R are nearly
identical. The residues p6G and p8R form a special pair
such that any canonical TCR contact will necessarily
Figure 1. Cytotoxicity and IFN-c production assays using native peptide and APL with substitutions at p6 and p8. (A)
51Cr-release
cytotoxicity assay was performed using increasing concentrations of native Ins B15–23 peptide with P815 target cells and G9C8
cloned T cells as effectors at an E:T ratio of 10:1 following 4 h of incubation. IFN-c production was measured by ELISA following
incubation with P815 cells and increasing concentrations of B15–23 peptide after 24 h incubation. Proliferation is shown by
[
3H]thymidineincorporationincpmfollowingincubationofG9C8clonedTcells,intriplicate,withincreasingconcentrationsofIns
B15–23peptide. (B) P815target cellswerefirstincubatedwith
51Cr-sodiumchromate andsecondly withdifferent concentrationsof
native peptide (NAT), irrelevant control peptides (LLO and HA) and peptides altered at position 6 and position 8. The G9C8 cloned
T cells as effectors were added to the plates at an E:T ratio of 10:1. Data are shown for a peptide concentration of 1 lg/mL. The
backgroundwhen effectors and targets were incubated in the absence of peptidewas 8.6% in this assay. The data arepresented as
percentage of specific lysis. Each value corresponds to the average of duplicate samples. Results shown represent one of at least
twoindependentassays.(C)G9C8clonedTcellswerestimulatedbypeptide-pulsedP815cellsatfivepeptideconcentrationswithin
the range 0.008–5 lg/mL.IFN-c production at 1 lg/mL is shown. Supernatantswere tested in duplicate taken after 24-h incubation
at 37
C. Results correspond to one of two independent experiments. The limit of detection for the assay was 0.27 U/mL.
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p7E (Fig. 5A).
It is apparent that even the slightest conservative
alteration (e.g. p6G ?A and/or p8R ?K) will have
important consequences on the canonical TCR affinity,
as shown in the T cell recognition results. As seen in
Fig. 5A, the Ins peptide backbone “leaps upward” from
p6 to p8, relative to the b-sheet floor of the groove
because residues 73Wand 147W in the H2-K
d molecule,
located across from each other, form a barrier over
which the antigenic peptide must “climb” [29]. Our
molecular simulation has the guanidine side chain of
p8R reaching backwards to p6G and being on the same
level above the b-sheet floor. Such a unique arrange-
ment would render these residues as prime contact
residues for the canonical cognate TCR [25, 26, 28, 30].
In the various substitutions at p6 and p8 modeled by
molecular simulation, it has not been possible to
duplicate this arrangement with any degree of physi-
cochemical similarity. For example, the complex of
H2-K
d with the p6H variantof the Ins peptideshowsthat
Figure 3. Antagonism of IFN-c production using APL with
substitution at p6 (A) and p8 (B). P815 cells were pulsed with
5 lg/mL of native peptide, washed, and then incubated with
different concentrations of the peptide variants G6H (A) and
R8L (B) (range 0.03–10 lg/mL). G9C8 cloned T cells were added
for a further incubation of 24 h. IFN-c release was determined
by ELISA and results expressed in U/mL. The baseline shown
here corresponds to the IFN-c production of the APC
preincubated with the native peptide but without addition of
APL.
Figure 4. MHC-APL-binding assays of the APL with substitu-
tions at p6 and p8 of the Ins B15–23 peptide. The binding of the
APL at p6 and p8 to the MHC molecule is shown at a peptide
concentration of6.25 lg/mL.All the APL, forp6 or p8,fall below
the baseline (given by the MHC binding of RMAS-K
d cells
stained with the FITC-conjugated anti-K
d mAb but without the
addition of any peptide), and the binding of the native peptide
(NAT) is just above baseline levels. By contrast, good binding to
the H-2K
d molecule is seen for the peptides LLO, HA and G9V
(NAT with the residue valine substituting glycine at p9,
previously shown to bind well to the MHC [21]).
Figure 2. Antagonism of cytotoxic response with APL G6H (A)
and R8L (B). P815 cells were incubated with
51Cr-sodium
chromate and with Ins B15–23 (1 lg/mL). The cells were then
washed,andfurtherincubatedwiththeAPLG6H(A)andR8L(B)
at concentrations ranging from 0.03 to 10 lg/mL. The G9C8
cloned T cells were then added to the plate at E:Tratios of 10:1
(A) and 8:1 (B). After 4-h incubation, supernatant was assayed
for
51Cr release. Results were expressed as % specific lysis. The
baseline shown here corresponds to the cytotoxicityto the APC
preincubated with the native peptide but without addition of
APL.
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solvent and TCR contact, while the side chain of p8R is
raised upward (Fig. 5B). Such significant changeswould
make it difficult for the cognate TCR to productively
engage this variant complex in the same manner as the
native peptide complex, as also verified experimentally
(Fig. 1–3).
The comparisons of the native residues p6G and p8R
with p6H and p8L are shown in Fig. 5C–F. Note that in
the native complex, p8R is almost on the same level
above the b-pleated sheet of the H2-K
d molecule as p6G,
while p7E points to the side and p5C points into the
groove (Fig. 5A).
Position 8 of the complex of K
d with Ins B15–23/
B22Leu (p8L) in Fig. 5F shows the uniqueness of the
native residue at this position. There is little change in
the orientation of the proximal residues from H2-K
d and
the side chain of p8L is essentially in the same
orientation as the methylene groups of native p8R
(Fig. 5E). The lack of the terminal guanidine group with
its charged nitrogen makes all the difference as far as
Tcell recognition of this important residue is concerned.
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TheinteractionofTcellswithpeptide-MHC complexesis
of considerable importance both for positive and
negative selection of mature T cells in the thymus as
well as for activation of T cells in the periphery. In the
thymus, antagonist peptides may induce or impair
positive selection (reviewed in [31]). Overall, the
evidence suggests that positive selection is promoted
by low-affinity self-peptides. Conversely, negative selec-
tion is triggered by high-avidity interactions, together
with other influences outside the thymus [32]. In the
periphery, the mode of triggering of the TCR following
binding to the MHC-peptide complex determines
whether the cells are fully activated to perform effector
functions, or partially stimulated or antagonized.
We have considered the properties of the Ins B15–23
peptide that stimulates a considerable percentage of
CD8 T cells involved in the very early phases of
pathogenesis of autoimmune diabetes in the NOD
mouse [15]. This peptide fits reasonably well into the
H-2K
d groove with the p2Y providing the primary
anchor, and the poor p9G the secondary anchor, mainly
through its free carboxylate end [21], as expected for a
peptide binding to the H-2K
d molecule. This would
explain why the T cells require relatively high peptide
concentrations to trigger effector functions. However,
perhaps because of the relatively poor MHC binding of
the peptide, thymic selection of the cells clearly occurs
and these cells are found in the very early insulitis [33],
even before other specificities, which become dominant,
appear [34]. When the cells encounter sufficiently high
concentrations of peptide, as in the islets, they can show
potent cytotoxicity (at concentrations of 40 ng/mL,
Fig. 1). The concentrations of peptide that stimulate
cytotoxicity are less than those required for IFN-c
productionor for proliferation(200 ng/mL) asshownin
Fig. 1.
Peptides that can bind to different MHC molecules
use different residues to bind to the MHC or TCR as
shown for the gp33 peptide of LCMV presented by both
K
b and D
b molecules [35]. Commensurate with this, APL
used by LCMV to escape host defenses will have a
different effect on the T cells that are restricted by
different MHC types. For all antigenic peptides, such as
the Ins B15–23 peptide, that bind to H2-K
d,t h e
conformation of the peptide in binding to the MHC
molecule is important for determining the TCR contacts
[2,24–28,36,37]. Inthecurrentstudy,weconcentrated
on the TCR contact residues 6 and 8, the two peptide
residues not tolerant of even conservative substitutions,
which point into the solvent and are high above other
peptide residues, to look for antagonistic effects. In fact,
most of the substitutions, to a greater or lesser extent
antagonize the effector functions, but we have focused
on those that are inhibitory at a low peptide concentra-
tion. Choice of antagonist peptide would be dictated by
the lowest concentration of peptide that could inhibit
both cytotoxicity and IFN-c production. These peptides
could potentially be used in the control of pathogenic
G9C8-like CD8 T cells in damaging islet beta cells.
Itis notablethat the substitutions atp6 of the peptide
have a greater antagonistic effect than those at p8, as
more of the substitutions at p6 antagonize the
cytotoxicity of the CD8 Tcells. There are several possible
reasons for this. P6G is a TCR-CDR3 contact point, and
this can be the most crucial of peptide-TCR contacts.
Furthermore, in this case, the p6 amino acid is glycine,
the simplest, smallest and most flexible of amino acids.
The peptide conformation in the MHC-peptide surface is
·
Figure 5. Molecular modeling of H-2K
d–Ins B15–23 and mutated B15–23 peptides. (A) TCR view of the H-2K
d–Ins B15–23 complex,
and side view of the peptide chain as bound in the groove of H-2K
d. This simulated structure is based on the crystal structure of
H-2K
d in complex with an influenza nucleoprotein peptide [29]. Several modes of structural rendering are shown simultaneously
in order to appreciate how the peptide fits into the groove. The antigenic peptide is in space-filling form with its carbon atoms
shown in green, nitrogen in blue, oxygen in red, hydrogen in white, and sulfur in orange. The a1a2 domain of the molecule is
depicted according to its secondary structure in different regions: a-helix in red, b-pleated sheet in turquoise and random coil in
grey. The solvent-accessible surface of the a1a2 domain is shown in grey with colorings according to the electrostatic surface
potential(blueforpositive,redfornegativeandintermediatehuesforneutral).Thesurfaceoftheheavychainismadetransparent
so that peptide residue p2Y that is buried in pocket B, as well as the heavy chain residues making contact with the insulin peptide
can be seen, albeit in a lighter color. These residues are shown with their carbon atoms in orange, while the color convention for
the other atoms is identical to that for the antigenic peptide. (B) Modeled structure of the H-2K
d molecule with the Ins B15–23 p6H
variant peptide, in the same orientation as the figure for the corresponding complex of the native peptide (A). Rendering and color
conventions as in (A). (C) Molecular environment in p6 of the modeled complex with view of p6 containing the insulin peptide
B15–23/B20G (p6G) residue and surrounding MHC heavy chain amino acids, in the complex of H-2K
d and Ins B15–23, as seen from
above (TCR view). Color, surface electrostatic, and transparency conventions are as in (A). Some of the surrounding residues are at
a distance longer than 4  , but are shown for comparison with (D). (D) View of p6 of the complex of H-2K
d with Ins B15–23/B20H
(p6H),inthesameorientationandconventionsasin(C).Allthesurroundingresiduesfromtheheavy chainareata distanceofless
than 4  . (E) View of p8 containing the Ins B15–23/B22R (p8R) residue and surrounding heavy chain amino acids, in the complex of
H-2K
d and Ins B15–23, as seen from above (TCR view). Representations, color, surface electrostatic, and transparency conventions
areasin(A).Allthesurroundingresiduesfromtheheavy chainareatadistanceoflessthan4  .(F)Viewofp8ofthecomplexofK
d
with Ins B15–23/B22Leu (p8L), in the same orientation and conventions as in (E).
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substitution including alanine, which has the closest
structure to the small glycine. It is highly likely that the
same non-stimulatory or antagonistic effects would
occur for any TCR that could recognize the K
d-B15–23
MHC-peptide complex. In several studies, it has been
shown that for particular MHC-peptide complexes,
cognate TCR engagement crucially depends on the
central peptide residue that is in contact with CDR3a
and b of the TCR. In fact, especially for MHC class I-
restricted recognition, alteration of a central residue
might turnan agonistpeptideintoanantagonist [30]. In
the case of an autoimmune disease, there may be
recognitionofaputativeinitialpathogenicpeptide-MHC
combination by more than one type of TCR. In such
cases, asingleAPLcannotbeexpected to“silence” allthe
pathogenic T cell clones as the exact orientation in the
different TCR/peptide/MHC recognition complexes
might differ [24]. It might then be necessary to use a
mixture of APL, each differing slightly from the native
peptide,andusingunnaturalaminoacidsifnecessary,in
order to introduce the slightest of changes at putatively
important TCR recognition sites [30]. We also note that
the concentrations of the antagonist peptide used in this
case are 10–50 times lower than that of the native
peptide, and as such compare well with the correspond-
ing ratios in other MHC class I APL [38]. Thus far there
have been three autoimmune-related TCR-MHC II-
peptide structures available, but none concerning
MHC I complexes [39–41]. The two human structures
have the TCR in an off-diagonal mode of interaction,
while the mouse structure is in the more common
diagonalinteraction.Inallthese,aswellasinothercases,
itisdifficulttoextrapolatefromthemodeandstrengthof
TCR-MHC-peptide interaction the extent of reactivity/
pathogenicity of the respective T cell clone [37].
The effect of peptide substitutions for a self-peptide
involved in autoreactive responses leading to diabetes is
important practically, as APL could potentially be used
for human therapeutic trials in type 1 diabetes.
Expression of altered insulin that includes a change in
p2Yof the B15–23 insulin peptide has a profound effect
on the recognition of autoreactive cells within the NOD
mouse [42]. It is most likely that this occurs because of
alteration of the principal MHC-binding residue for the
insulin-reactive CD8 T cell epitope as shown in our
previous study [21], in addition to the effects that may
occur for the CD4 T cells in that model system. The Ins
B9–23 peptide that may bind to H2-A
g7 of the NOD
mouseMHC class IImaydo so indifferentregisters, with
B16Yeither as p4 anchor, and identical in register to the
HLA-DQ8-Ins complex [43], or as p5 TCR contact
residue [44]. Regardless of the exact core nonamer, it is
very important to consider both CD4 and CD8 epitopes
when proposing to use either native peptides or APL for
immunotherapy.Furthermore, the detrimentaleffectsof
a cytotoxic epitope to an overlapping CD4 epitope for
inducing tolerance in NOD mice have been shown for
another region of the proinsulin molecule that en-
compasses both a CD4 (Ins B24–C32) and a CD8 (Ins B
25–C34) epitope [45]. Recently, three independent
studies have documented proinsulin-specific CD8 cells
from peripheral blood of patients with type 1 diabetes
who bear the most abundant human MHC class I protein
(HLA-A2) [46–48]. One of these peptides was the Ins
B10–18 peptide that overlaps with the B13–21 core
nonamer that binds to HLA-DQ8 and is recognized in
that context by CD4 T cells from patients with type 1
diabetes [16]. Whether proinsulin is the primary
autoantigen in human type 1 diabetes remains to be
established.
Our data suggest that any changes in p6 and p8
would have the added effect of actively reducing
cytotoxicity and IFN-c production of any Ins B15–23-
reactive CD8 T cells. Unlike T cells recognizing other
autoantigens such as islet-specific glucose-6-phospha-
tase catalytic subunit–related protein (IGRP), Ins
B15–23-reactive CD8 T cells appear earlier in the
pathogenic process and are detectable when insulitis
first appears [15, 34]. The dominance of proinsulin as
the primary autoantigen in NOD mouse diabetes is
shown by the fact that NOD mice made tolerant to IGRP
are not protected from type 1 diabetes, compared with
micemadetoleranttoproinsulin[49].Unlikethestudies
on the prevalent IGRP-reactive cells that increase in
number and avidity with time [50], these insulin-
reactive T cells are of relatively low avidity and do not
expand in the same manner. However, the insulin-
reactive CD8 T cells are capable of being highly
pathogenic [14] and the ability to antagonize such cells
and prevent them from causing early islet damage is
likely to add benefit in protection against diabetes. It
may also be possible to administer APL in mannosylated
form, thus enhancing their uptake by professional APC
100 to 1000-fold [51]; these professional APC can also
cross-present via the MHC class I pathway [52]. In
summary, our study provides both functional and
structural evidence for the possible application of APL
with mutated p6 and p8 of B15–23 in preventing
diabetes. It is likely that this would have the greatest
effect combined in a peptide that would also influence
CD4 T cells. We will test this hypothesis in vivo in the
near future.
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Clones and cell lines
T cell clones
G9C8 CD8 T cell clones were maintained in Bruff's medium
(Invitrogen), supplemented with 5% FCS, and 5 U/mL IL-2
(supernatant from EL4 cell line), at 37
Ci n5 %C O 2. The cells
were fed every 2 weeks with islets isolated from young NOD
mice by collagenase digestion, as previously described [14].
Cell lines
P815 cells are K
d-expressing mast tumor cells. RMAS cells-K
d
cells (kindly provided by A. Quinn of University of Toledo,
USA) are a TAP-deficient lymphoma cell line, transfected with
H2-K
d. The MHC class I molecules are stabilized on the surface
of these cells by bound peptide [53].
Both cell lines were maintained in complete medium (RPMI
1640mediumsupplementedwith5%FCS,2 mML-Glutamine,
1% PSF and 50 lM 2-mercaptoethanol) at 37
Ci n5 %C O 2.
Peptides
The native peptide Ins B15–23 (LYLVCGERG) was synthesized
by the Keck facility, Yale University. The APL of the native
peptide B15–23 substituted with all of the amino acids at p6
and p8, separately, were synthesized by Chiron Technologies,
USA. The nomenclature adopted for the APL includes a letter,
representing the native amino acid to be replaced; a number,
representing the position in the peptide where the substitution
takes place; and a second letter, representing the newly
introduced amino acid.
Assays
Chromium-release cytotoxicity assay
Chromium-release assays were performed as previously
described [15]. Target P815 cells were incubated with
0.1 lCi
51Cr-sodium chromate (Amersham) at 37
C for 1 h.
The cells were then washed twice, and 10
4 cells were further
incubated with peptide concentrations ranging from
0.0016–5 lg/mL in round-bottom 96-well plates. The native
peptide and each of the 19 peptides substituted at p6 and at p8
were tested together with two control peptides from
listeriolysin (LLO) and hemagglutinin (HA). G9C8 cloned
Tcells (10
5 cells) were added to the plates at an effector:target
(E:T) ratio of 10:1. The assay mixture was incubated for 4 h at
37
C. Supernatant was assayed for
51Cr-release in a c-counter.
Results were expressed as % specific lysis determined as
[(cytotoxic release - Min)/(Max - Min)]  100, where the
spontaneous lysis corresponds to the minimal release (Min),
and the lysis provoked by addition of hydrochloric acid
corresponds to the maximal lysis (Max).
Antagonist cytotoxicity assay
This is a modification of the standard cytotoxic assay described
above, and based on two-stage antagonism assays [9]. P815
target cells were incubated with
51Cr-sodium chromate and
with a pre-titrated concentration (1–5 lg/mL) of the agonist
peptide (Ins B15–23) at 37
C for 1 h. The cells were then
washed twice and 10
4 cells further incubated at 25
C with
different APL at varying concentrations in 96-well plates for
another hour. Then, 10
5 G9C8 cloned T cells were added
(effector-target ratio of 10:1). This E:T ratio was chosen
following previous titration experiments. The assay mixture
was incubated for 4 h at 37 C. Supernatant was assayed for
51Cr release in a c-counter. Results were expressed as %
specific lysis (% SL) as above. A further calculation was then
performed to express % inhibition of lysis (% inhibition =
((Baseline (B) - cytotoxic release (X))/(Baseline - Min))  100.
T cell proliferation assay
NOD splenocytes (10
5) as APC were irradiated (3000 rad) and
incubated with native peptide (B15–23) at 25
C for 1 h.
Cloned T cells (10
4) were added and after 72 h incubation at
37
C, [
3H]thymidine was added for a further 14–18-h
incubation. Plates were harvested and [
3H]thymidine uptake
was measured in a b-counter.
IFN-c assay
In IFN-c production assays, P815 cells (10
5) were incubated
with native peptide (B15–23) at 25
C for 1 h. Cloned T cells
(10
4) were then added and after 24-h incubation at 37
C, the
supernatantwas harvested.IFN-cproductionwas measuredby
ELISA using antibodies purchased from BD Bioscience, using
standard methodology [15]. For the antagonist assays, P815
cells (10
5) were incubated with native peptide at 25
C for 1 h.
The cells were then washed, and incubated for another hour
with different variant peptides at varying concentrations.
Finally, cloned T cells (10
4) were added and after 24-h
incubation at 37 C, the supernatant was harvested and
analyzed for IFN-c production as above.
H-2K
d-binding assay
H-2K
d is stabilized by peptide on the surface of RMAS-K
d cells.
This is a standard assay for testing binding of MHC class I
peptides to the MHC. The binding assay was performed as
previously described [21]. Briefly, RMAS-K
d cells were
incubated at 30
C [54] for 16 h with four different
concentrations of peptide (ranging from 0.39 to 25 lg/mL).
Subsequently, cells were stained on ice with FITC-conjugated
SF1–1.1 mAb (BD Bioscience) that stains H-2K
d. Binding of
peptide was measured by the degree of staining with SF1–1.1
and expressed as mean channel fluorescence (MCF) measured
by flow cytometry.
Molecular modeling
Structural homology modeling of the H-2K
d molecule with the
Ins B15–23 peptide and its variants was performed, based on
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d-influenza A/PR8/34
nucleoprotein peptide 147–155 complex ([29]; PDB code
2FWO) as previously described, at an ambient pH value of 7.0
[21, 55]. Specifically, the Ins B15–23 residues (and APL where
appropriate) were substituted by selecting the most suitable
rotamer from a library of rotamers provided by the program
Insight/Discover of Accelrys (San Diego, CA). Thereafter
energy minimization of the H-2K
d-Ins B15–23 complex was
performed by the program Discover using 1000 steps of the
steepest gradient method to be followed by 1000 steps of the
conjugate gradient method. The decrease in energy was
continuouswithnoabruptchanges.Extensionof theconjugate
gradient minimization to 10 000 steps (both here and in
previous works [45, 55–57]) yielded small decreases in the
energy values with no significant shifts in the positions of MHC
or antigenic peptide residues. No cross-terms were used in the
potential function. Water molecules from the crystal structure
were deleted and not taken into account for the minimization.
Thisminimizationprocedureresultedinminimalchangeinthe
coordinates of Ca atoms of the H-2K
d molecule, in similarity to
several previous works with MHC I and II molecules, with a
root mean square deviation of K
d backbone atoms of ca. 0.51  
for autologous (as here) or homologous molecules to 1.33  
for xenogeneic MHC molecules (e.g. from HLA-A2 to H2-K
d)
[21, 45, 55–57]. This approach is considered closer to the in
vivo situation, where it has been shown that different peptides
bound to the same MHC I molecule induce different
conformations on the MHC residues contacting the peptide
[22]. Representations of all or part of the modeled H-2K
d-Ins
B15–23 complex were accomplished on a personal computer
using the program DSViewer Pro Suite 6.0 of Accelrys. Unless
otherwise stated, all representations of single antigenic
residues,inparticular positions,depictallheavychainresidues
that haveatleastoneatomatadistanceof<4  fromanyatom
of the particular peptide residue. The .pdb coordinates of the
modeled H2-K
d–Ins B15–23 complex and its variants are
shown in Supporting Information.
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